Senator Bernie Sanders pointed to UnitedHealth's $5.48 billion in second-quarter 2026 profit as evidence the company's requested 25% average rate increase for its DC small-group HMO and PPO plans could not be justified (Sanders, July 21, 2026).

The claim joins two figures a rate actuary keeps separate: trailing consolidated GAAP earnings across every state and product line, and one prospective state filing that must clear its own morbidity and trend assumptions.

Key Takeaways

  • Roughly half the parent's operating profit is not insurance. Optum produced $65.7 billion of revenue and $4.0 billion of operating earnings against UnitedHealthcare's $86.0 billion and $3.9 billion, and Optum never touches the DC filing.
  • UnitedHealthcare's operating margin is 4.6%, on 48.5 million members whose count fell 525,000 sequentially, which is the segment the DC small-group book actually sits in.
  • The relevant benchmark is 10.4%, the DC-wide small-group average, against CareFirst at 9.8% and 4.5% and Kaiser at 8%. UnitedHealthcare's ask is more than double its local market.
  • The MLR backstop runs on a three-year rolling average, requiring 80% of small-group premium on claims and quality improvement, so it corrects overpricing years later rather than at approval.
  • A national median of 14% across 77 preliminary 2027 filings, with 20 insurers above 20%, puts the DC request inside a national cycle rather than ahead of it.

The $5.48 Billion Is Three Businesses Blended

Sanders made the link explicit: "Corporate greed is UnitedHealth making a $5.48 billion profit last quarter (up 60% from last year), spending $33 billion in stock buybacks since 2022, paying its CEO over $60 million last year while it works to hike premiums by up to 25% next year." The arithmetic checks against the release: $5.48 billion against $3.41 billion a year earlier is a 60.7% increase (UnitedHealth, July 16, 2026).

The consolidated number aggregates segments with different economics. It sits on $112.0 billion of revenue and $8.0 billion of operating earnings, up 55%. UnitedHealthcare, the arm that underwrites DC small group, produced $86.0 billion of revenue and $3.9 billion of operating earnings, a 4.6% margin, serving 48.5 million people across commercial, Medicare and Medicaid, with membership down 525,000 sequentially. Optum produced $65.7 billion and $4.0 billion on a 6.2% margin.

Inside the insurance arm, the medical care ratio improved to 86.7% from 89.4%. A falling ratio is better carrier performance, and roughly 40% of that 270-basis-point move traced to $860 million of net favorable prior-period development, mostly on 2026 dates of service, rather than to pricing.

That reserve dynamic is national and blended across every state and product. It carries no information about whether one DC small-group HMO book, priced against DC provider contracts, DC morbidity and DC risk adjustment transfers, is running rich or thin.

What the Filing Has to Clear, and Against Whom

DC's Department of Insurance, Securities and Banking published preliminary 2027 rates for 181 plans across CareFirst BlueCross BlueShield, Kaiser Permanente and UnitedHealthcare on June 8, 2026 (DC DISB). UnitedHealthcare proposed roughly 25% across two small-group HMO products and its PPO plan.

The peer comparison is where the request is unusual. CareFirst proposed 9.8% for small-group HMO and 4.5% for PPO, Kaiser proposed 8%, and the DC-wide small-group average lands near 10.4%, with the individual market around 9.5%. The ask is more than double the jurisdiction's blended average, which is the comparison a rate actuary draws.

FigureWhat it measuresRelevant to the DC rate filing?
$5.48B Q2 2026 net earningsConsolidated GAAP profit, all segments, all statesNo, not a rate-filing input
86.7% medical care ratioUnitedHealthcare's national blended claims-to-premium ratioDirectional context only, not DC-specific
25% proposed DC small-group increaseUnitedHealthcare's own HMO/PPO filing for one marketYes, the actual filing under review
10.4% DC small-group market averageBlended average across CareFirst, Kaiser, UnitedHealthcareYes, the relevant peer benchmark
$33B buybacks since 2022 (per Sanders)Parent-level capital allocationNo, but shapes public/political scrutiny

An actuarial memorandum supporting the filing justifies the rate against prospective inputs: projected medical and pharmacy trend, expected morbidity of the specific pool, provider unit-cost changes in DC-area contracts, projected risk adjustment transfers, administrative expense and premium tax load, and a contribution-to-surplus assumption the regulator evaluates separately for reasonableness. None of them references consolidated net income, the buyback program or executive pay.

That cuts both ways. A regulator tests whether the DC book's own projected claims and expenses support 25%, not whether the parent can afford to charge less. If DC small-group morbidity, reimbursement or pool composition deteriorated beyond what 2026 rates assumed, a 25% correction can be supportable in the same quarter the parent reports record earnings elsewhere.

The national cycle makes that plausible. Preliminary filings from 77 ACA Marketplace insurers across 16 states and DC show a median proposed increase of 14% for 2027, with 20 requesting more than 20% (KFF, July 2026). KFF attributes it to underlying medical and drug trend near 10%, above the roughly 8% of recent years, plus a sicker pool that added about four points to 2026 premiums and is expected to add four more (Peterson-KFF). Small group is a distinct segment from the individual marketplace, but the cost drivers are shared.

The Correction Exists and Arrives Three Years Late

The mechanism that catches overpriced rates is the ACA medical loss ratio rule rather than the rate review itself. Individual and small-group insurers must spend at least 80% of premium on claims and quality improvement, measured as a three-year rolling average by state and market segment, with 85% in large group (CMS; NAIC).

That is retrospective. If the DC book collects 25% in 2027 and claims come in materially better than priced, the calculation forces a rebate on a rolling three-year lag rather than an immediate clawback. So the corrective already exists, operating on a multi-year cycle at the state-and-product level where the risk was written, which is a different unit of analysis from the parent income statement the critique cited.

What fills the gap in the meantime is political rather than actuarial. UnitedHealth's proxy confirms Stephen Hemsley draws a $1 million base salary with no annual cash incentive, alongside a one-time $60 million equity award in nonqualified stock options cliff-vesting over three years with no further grants planned (2026 proxy). Public trackers put repurchases near $7 billion in 2022, $8 billion in 2023 and $9 billion in 2024, with at least $5 billion guided for 2026, broadly consistent with the cumulative $33 billion cited.

Neither figure is a rating input. Both are funded from the same consolidated cash flow that includes UnitedHealthcare's insurance margins, and DC's review includes a public hearing in September 2026 where testimony citing parent-level results is a normal feature. The commissioner has authority to challenge the contribution-to-surplus assumption specifically, alongside trend and morbidity. That is the checkpoint where a record quarter actually reaches the filing, and it reaches the margin assumption rather than the trend.

Further Reading

Sources